Global Plaque Psoriasis Treatment Market Report and Forecast 2023-2031

Global Plaque Psoriasis Treatment Market Report and Forecast 2023-2031

Global Plaque Psoriasis Treatment Market Outlook

The global plaque psoriasis treatment market is expected to grow significantly during the forecast period of 2023-2031. The increasing prevalence of plaque psoriasis worldwide, coupled with the growing investment in research and development activities, is driving the growth of the market. The global plaque psoriasis treatment market is likely to grow at a CAGR of 3% during the forecast period.

Plaque Psoriasis Treatment Market: Introduction

The global plaque psoriasis treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. Plaque psoriasis is a chronic autoimmune disorder that affects the skin, characterized by red, scaly patches that can be painful and itchy. The lack of effective treatments for plaque psoriasis has been a major challenge for healthcare providers and researchers worldwide. The report covers the market for plaque psoriasis treatment and provides a detailed analysis of the market size, growth, and trends.

The plaque psoriasis treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as biologics and small molecules, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.

Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of plaque psoriasis, potentially improving patient outcomes and reducing healthcare costs. As a result, the global plaque psoriasis treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.

Plaque Psoriasis Epidemiology

The global epidemiology of plaque psoriasis varies based on factors such as geographic location, ethnicity, and age. The prevalence of plaque psoriasis ranges from 1% to 3% of the population worldwide. The disease affects both genders and can occur at any age, with the most common age of onset being between 15 and 35 years.

The plaque psoriasis treatment market is highly competitive, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for plaque psoriasis has led to the emergence of many companies focusing on the development of innovative therapies for this disease.

Plaque Psoriasis Treatment Market Segmentations

The market can be categorised into diagnosis method, treatment type, therapy type, route of administration, drug type, population type, treatment channel, end user, distribution channel, and region.

Market Breakup by Diagnosis Method

• Blood Tests
• Skin Prick Test
• Patch Test
• Biopsy
• Others

Plaque Psoriasis Treatment Market Breakup by Treatment Type

• Biologics Drugs
• Apremilast
• Atanercept
• Infliximab
• Adalimumab
• Ustekinumab
• Secukinumab
• Ixekizumab
• Guselkumab
• Tildrakizumab
• Certolizumab
• Others
• Systemic Drugs
• Methotrexate
• Soriatane
• Otezla
• Sotyktu
• Cyclosporin
• Others
• Phototherapy
• Ultraviolet B (UVB)
• Topical Drugs
• Calcipotriene
• Tazarotene
• Calcineurin Inhibitors
• Roflumilast
• Salicylic Acid
• Others
• Others

Market Breakup by Therapy Type

• Monotherapy
• Combination Therapy

Market Breakup by Route of Administration

• Oral
• Tablets
• Capsules
• Parentals
• Intravenous
• Intramuscular
• Topicals
• Others

Plaque Psoriasis Treatment Market Breakup by Drug Type

• Over the Counter
• Prescription
• Branded
• Generics

Market Breakup by Population Type

• Children
• Adults
• Male
• Female
• Geriatrics
• Male
• Female

Market Breakup by Treatment Channel

• Public
• Private

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Market Breakup by Region

• North America
• United States of America
• Canada
• Europe
• United Kingdom
• Germany
• France
• Italy
• Others
• Asia Pacific
• China
• Japan
• India
• ASEAN
• Australia
• Others
• Latin America
• Brazil
• Argentina
• Mexico
• Others
• Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Plaque Psoriasis Treatment Market Scenario

North America dominates the rare diseases treatment market, followed by Europe and the Asia Pacific. The high prevalence of rare diseases in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for rare diseases treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about rare diseases and the rising healthcare expenditure in the region.

The market is highly fragmented, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for rare diseases has led to the emergence of many companies focusing on the development of innovative therapies for these diseases. The market for biological drugs is expected to grow significantly during the forecast period, driven by the increasing adoption of innovative therapies such as gene therapy and cell therapy.

Key Players in the Global Plaque Psoriasis Treatment Market

The report gives an in-depth analysis of the key players involved in the plaque psoriasis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Pfizer Inc.
• Abbvie Inc.
• Novartis AG
• Amgen Inc.
• Boehringer Ingelheim International GmbH.
• Merck & Co Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• AstraZeneca
• Ampio Pharmaceuticals Inc.
• Eli Lilly and Company
• Novartis International AG
• Sun Pharmaceuticals Industries Ltd.
• Stiefel Laboratories
• UCB S.A.
• LEO Pharma
• Cipla Inc.
• Rowan Bioceuticals
• Glenmark Pharmaceuticals
• Win-Medicare Pvt. Ltd.
• Sanofi S.A.